Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Norepinephrine + dopamine refers to the combination of two endogenous catecholamine neurotransmitters and hormones, both of which are also used as pharmaceutical agents, primarily in critical care settings. Norepinephrine (noradrenaline) acts mainly as a potent vasoconstrictor via alpha-adrenergic receptor agonism, increasing blood pressure with minimal effect on heart rate at standard doses. Dopamine is a precursor to norepinephrine and exerts dose-dependent effects; at low doses it stimulates dopaminergic receptors (vasodilation in renal/splanchnic beds), at moderate doses it stimulates beta-1 adrenergic receptors (increasing cardiac contractility and heart rate), and at high doses it activates alpha-adrenergic receptors (vasoconstriction). Both drugs are used intravenously for acute management of shock states such as septic shock or cardiogenic shock to support blood pressure and organ perfusion[8][6]. They act through different but overlapping mechanisms on adrenergic receptors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on norepinephrine + dopamine.